Mounjaro and Menopause: What UK Women Need to Know (2026 update)
Key Takeaways (2026 Update)
Mounjaro can support weight loss in menopause
Combining Mounjaro with MHT/HRT may enhance results
Muscle preservation requires protein + resistance training
NHS access is limited and evolving in the UK
Medication works best alongside lifestyle and behavioural support
Mounjaro and Hormone Therapy - Why We’re Talking About This
Since this article was first published in September 2025, important new research has emerged on Mounjaro and menopause in the UK.
If you’re in the thick of menopause and feeling like your body has suddenly stopped playing by the rules, you’re not alone. Weight gain that won’t budge, hormone havoc and the sense that your GP doesn’t quite “get it” are daily struggles for so many women I work with.
And now there’s increasing buzz around Mounjaro® (tirzepatide), a drug originally developed for type 2 diabetes and now approved for weight management and the research specifically relevant to menopausal women has moved on considerably in the past few months.
What Exactly Is Mounjaro?
Mounjaro (tirzepatide) is a once-weekly injectable that targets both GLP-1 and GIP hormones, helping to regulate blood sugar and reduce appetite. This dual mechanism distinguishes it from GLP-1-only drugs like Wegovy and that’s one reason it’s attracting interest among midlife women navigating the metabolic slowdown of perimenopause and postmenopause.
Where Menopause & Mounjaro Intersect
As oestrogen levels fall, metabolism shifts, not because of personal failings, but due to hormonal change. This can mean more insulin resistance, increased abdominal fat and less responsiveness to habits that worked in the past.
Early research suggests tirzepatide may help reduce central adiposity (belly fat) across reproductive stages. While not a cure, it could become a supportive tool alongside nutrition, movement and lifestyle strategies.
A major post-hoc analysis of the SURMOUNT clinical trials (published in Obesity, 2025) confirmed that tirzepatide produces significant reductions in body weight and waist circumference across all reproductive stages - pre-, peri- and postmenopause - with 97–98% of women achieving at least 5% body weight loss versus 29–33% on placebo. Importantly, it also reduced waist-to-height ratio, a direct measure of central adiposity that is particularly pronounced during perimenopause.
That said, it's a supportive tool - not a standalone solution.
The Landmark 2026 Study: Mounjaro + MHT/HRT Together
This is the most significant update to this post.
A study published in The Lancet Obstetrics, Gynaecology, & Women's Health in January 2026 found that in postmenopausal women with overweight or obesity, concurrent use of hormone therapy was associated with greater weight loss and improved cardiometabolic outcomes during tirzepatide treatment. The Lancet
The study was led by researchers at Mayo Clinic and used real-world electronic health record data from 120 postmenopausal women who had been on tirzepatide for at least 12 months. Women using hormone therapy were carefully matched to non-users of similar age, BMI and health status.
Women using menopausal hormone therapy (MHT) lost about 35% more weight than women taking tirzepatide alone, according to senior author Dr Maria Daniela Hurtado Andrade. Mayo Clinic News Network In numbers: women using both treatments lost 17% of their body weight on average, compared to 14% in those not using hormone therapy - and nearly half (45%) achieved 20% or more weight loss, compared to 18% of those on tirzepatide alone. ScienceDaily
Researchers also noted that postmenopausal women on hormone therapy achieved outcomes closely resembling those in pre- and perimenopausal groups - suggesting the combination may help to close the gap that menopause itself creates. AJMC
Beyond weight, women using both tirzepatide and HRT also saw greater improvements in blood pressure, cholesterol and other markers of metabolic health. Paloma Health
What we don't yet know: This was an observational study, not a randomised controlled trial. The researchers caution that cause and effect cannot be confirmed - it's possible that hormone therapy users were already engaged in healthier behaviours, or that relief from vasomotor symptoms improved sleep and quality of life, making it easier to stay on track with diet and exercise. Mayo Clinic News Network Larger prospective trials are needed. But the magnitude of the difference is hard to ignore.
What About Muscle Mass?
This is a question I hear constantly, and it's especially relevant for women in midlife when muscle is already under pressure from declining oestrogen.
A 2025 systematic review of randomised controlled trials (published in PMC) found that tirzepatide treatment is associated with reductions in fat mass while maintaining the relative preservation of lean mass, with indicators of muscle composition remaining stable or showing signs of improvement. PubMed Central
The nuance, though, is that this isn't automatic. Data from the SURMOUNT-1 body composition analysis shows that roughly 75% of weight lost with tirzepatide is fat mass and 25% is lean mass - a ratio similar to that seen with placebo, despite greater total weight reduction. What that means in practice: adequate protein intake and resistance training matter enormously, particularly for women over 40 whose muscle protein synthesis is already less responsive than it was in their 30s.
This is exactly the kind of gap a coach can help fill.
Can You Access Mounjaro Through the NHS in the UK?
The situation has shifted significantly since this post was first published in September 2025.
Where things stand in 2026:
The phased NHS rollout has continued - but access remains uneven. A British Medical Journal investigation in January 2026 found that one in five local areas still lacked a functional NHS pathway for Mounjaro, and these regional gaps are reportedly pushing some patients toward an unregulated black market for GLP-1 drugs - which carries serious safety risks. International Business Times
The biggest development is the 2026/27 GP contract. Announced in February 2026, a new government obesity strategy introduces financial incentives for GPs to move weight management from specialist clinics into local surgeries, with practices in England offered a bonus of up to £3,000 for actively managing patients on weight-loss injections such as tirzepatide - supported by £25 million in ring-fenced funding. International Business Times
By July 2026, an £85 million programme co-funded by the government and manufacturer Eli Lilly is expected to launch, testing additional access routes through community pharmacies and digital health platforms. International Business Times
It is possible to access Mounjaro through the NHS, but at the moment this is quite tightly controlled and depends on specific clinical criteria.
Current eligibility (Year 1 — 2025/26):
NHS prescribing through primary care still requires:
BMI of 40 or above (or 37.5 for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds)
Four or more weight-related comorbidities: type 2 diabetes, hypertension, cardiovascular disease, obstructive sleep apnoea, or dyslipidaemia
Engagement with mandatory wraparound care (nutritional and behavioural support)
Future phases are expected to widen access to those with BMI 35–39.9 plus comorbidities, but timelines vary significantly by ICB. If you don't yet meet the criteria, private access is available - though costs apply. Always check your local ICB for the latest position.
What Research Says About Hormone Therapy and Mounjaro
A study presented at ENDO 2025 found that postmenopausal women using both Mounjaro and menopause hormone therapy (MHT) lost significantly more weight- 17% of body weight versus 14% with Mounjaro alone. A greater share (45% vs. 18%) achieved ≥20% weight loss EndocrineThe Cardiology Advisorgastroenterologyadvisor.com.
While promising, these results are early and not yet peer-reviewed. Larger trials will be needed to confirm the long-term benefits.
Safety & Interactions: What You Need to Know
Mounjaro, like any medication, can cause side effects - common ones include nausea, fatigue, or digestive changes.
1. Interaction with Oral MHT or Hormonal Contraceptives
Emerging data shows tirzepatide can reduce absorption of oral contraceptives by delaying gastric emptying, lowering peak concentrations and exposure levels healthed.com.auPubMedReproductive Health Access Project. While specific data for oral progesterone (as used in MHT) is limited, expert guidance cautions that the same mechanism may apply.
The British Menopause Society recommends non-oral routes for MHT if you’re on tirzepatide, like patches, gels or intrauterine devices, to ensure effective endometrial protection British Menopause Society.
*This information hasn't changed by March 2026. Tirzepatide can reduce the absorption of oral medications by slowing gastric emptying. The British Menopause Society recommends non-oral routes for MHT - patches, gels or intrauterine devices - if you're on tirzepatide, to ensure effective endometrial protection. Specific data for oral progesterone remains limited, but the same mechanism is thought to apply.
2. Holistic Support: Muscle, Protein and Lifestyle
Clinical commentary underscores that while these drugs can be impactful, they are not magic bullets. Lifestyle changes remain crucial and there are concerns about long-term effectiveness and resource strain on primary care The Guardian+1.
Given what we now know about lean mass loss, nutritional support is more important than ever alongside tirzepatide. Appetite suppression can make it easy to under-eat protein without realising - which matters enormously for women in midlife trying to maintain muscle, metabolism and energy.
Many women find that while medications like Mounjaro can support weight loss, they don’t address the wider picture of what’s happening in midlife - from energy and muscle loss to emotional load and changing stress tolerance. This is often where personalised support becomes important, helping you translate medical treatment into something sustainable in real life.
This isn’t just about weight - it’s about understanding what’s changing
For many women, conversations about medications like Mounjaro come at a point where something already feels off.
Weight changing in ways that don’t make sense.
Energy feeling harder to sustain.
Your body responding differently to things that used to work.
So it’s natural to look for solutions.
But as you’ve seen, this isn’t a simple decision.
Mounjaro works by affecting appetite, blood sugar and digestion - including slowing how quickly food and medication move through your system.
Which means it can also affect how other medications are absorbed, including some forms of MHT/HRT.
This is why it’s not just about whether something works -
but how it fits into the bigger picture of your body, your hormones and your overall health.
Why this can feel confusing
Because you’re often trying to make decisions without the full picture.
You might be:
dealing with symptoms that don’t feel like you
trying to manage weight that’s suddenly more resistant
hearing mixed messages about what’s safe, effective, or “worth it”
And all of this sits alongside a body that’s already changing.
It’s a lot to hold - especially on your own.
What matters most before making any decision
Before deciding whether something like Mounjaro is right for you, the most helpful step is often:
understanding what’s actually driving the changes you’re experiencing
Because without that, it’s easy to:
reach for solutions that don’t fully address the root cause
or feel like you’re constantly trying new things without clarity
Where to start
If this has raised questions for you, a good first step is to step back from “what should I take?” and instead focus on:
“What is my body actually asking for right now?”
→ Start with the Free PeriMenopause Blueprint
This will help you:
understand the connection between your hormones, metabolism and energy
see why things may have shifted - even if your habits haven’t
and begin to find a way forward that feels more grounded and less reactive
How My Coaching Supports You, On or Off Medication
Whether you’re weighing Mounjaro, already using it, or leaning toward non-medication routes, I’m here to support the whole of you.
As a certified menopause health coach, I help you:
Make sense of your body’s changes and reassure you it’s not your fault.
Navigate private access with clarity (if you don’t meet NHS criteria).
Rebuild your connection with food, movement and self-trust.
This isn't about quick fixes, it’s about sustainable, biology-aligned support.
Ready to Get Clear?
If you’re navigating Mounjaro, considering it, or simply feeling stuck with what’s happening in your body, you don’t have to figure it out alone.
Menopause coaching gives you personalised, evidence-informed support that helps you make sense of your options and build a sustainable approach that works in real life - whether that includes medication or not.
→Book your free Menopause Clarity Call
Explore further
If you’re still figuring out what kind of support you might need, these may help:
→ See how menopause coaching gives you structure, clarity and direction
→ Read: Menopause coaching vs therapy vs GP support - what’s right for you?
→ What results can you realistically expect from menopause coaching?
→ 5 Signs you are Ready for Support
This article reflects current research and evidence-informed practice. I work within the UKIHCA scope as a health coach and do not provide medical advice.
References & Evidence
Castaneda R et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. The Lancet Obstetrics, Gynaecology, & Women's Health. January 22, 2026. Link
Mayo Clinic News Network - New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause. January 22, 2026. Link
Tchang BG et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring). 2025;33:851–860. PMC12015656
Systematic review: Effects of tirzepatide on skeletal muscle mass in adults. PMC12394919, 2025. Link
NHS England - 2026/27 GP contract obesity strategy. Announced February 23, 2026
NHS England - Tirzepatide in primary care wraparound care guidance. Link
King's College London / BJGP editorial: Tirzepatide and the NHS - are we creating a two-tier obesity treatment system? January 2026. ScienceDaily
NHS England - Tirzepatide (Mounjaro) weight management eligibility, March 2025 NHS England
NHS Cheshire & Merseyside - phased rollout criteria, June 2025 onward NHS Cheshire and Merseyside
Lincolnshire ICB - eligibility breakdown and ethnic adjustments Lincolnshire ICB
Endocrine Society (ENDO 2025) - Mounjaro + MHT enhanced weight loss Endocrinegastroenterologyadvisor.com
British Menopause Society - interaction with oral progesterone and HRT route guidance British Menopause Society
Data on tirzepatide’s impact on oral contraceptive absorption healthed.com.auPubMedReproductive Health Access Project
GP commentary and NHS rollout context The Guardian+1
Coaching Benefits & Client Experiences
The Importance of Health Coaching for Holistic GLP-1 and Weight Management Support
Explains how Health Coaches play a key role in supporting clients on GLP-1 drugs by guiding them toward sustainable lifestyle changes that improve overall health and address the root causes of metabolic imbalance.GLP-1 Nutrition Support
Discusses the necessity to have nutritional meal plans aligning with GLP-1 medications and clients' goals, digestive symptom relief strategies, and menopause and hormone health support.
